Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: "biochemical recurrence" Clear all

Conditions: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration; Procedure · Other · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Irvine, California

Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions: Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography; Drug · Other · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia • Johns Creek, Georgia

Conditions: Prostate Cancer
Interventions: MUC-2-Globo H-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Adenocarcinoma, Prostate Cancer
Interventions: Transvesical Single Port Robotic Partial Prostatectomy, High-intensity focused ultrasound (HIFU); Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Male only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Control, Sipuleucel-T; Other · Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2015
U.S. locations: 18
States / cities: Berkeley, California • Laguna Hills, California • Aurora, Colorado + 13 more

Conditions: Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
Interventions: Olaparib, LHRH agonist; Drug
Lead sponsor: Rana McKay, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: La Jolla, California • Baltimore, Maryland • New York, New York + 2 more

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: RMC-5552; Drug
Lead sponsor: Nicholas Butowski; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: motexafin lutetium, photodynamic therapy; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions: PRL-02 injection, prednisone, dexamethasone, enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more

Conditions: Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Metastatic to Bone
Interventions: 68Ga PSMA-11 injection, Positron Emission Tomography/Computed Tomography; Drug · Procedure
Lead sponsor: Dana Mathews; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostatic Neoplasms
Interventions: Exisulind; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostate Cancer Patients Undergoing Radical Prostatectomy, High-risk Prostate Cancer
Interventions: FK-PC101, Standard of Care (SOC); Biological
Lead sponsor: Cellvax Therapeutics Inc; Industry
Eligibility: Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Gahanna, Ohio • Myrtle Beach, South Carolina

Conditions: Prostate Cancer
Interventions: MR-guided laser focal therapy; Device
Lead sponsor: HALO Diagnostics; Industry
Eligibility: 45 Years to 90 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2036
U.S. locations: 1
States / cities: Indian Wells, California

Conditions: Canker Sore
Interventions: Luminance RED Low Level Laser Therapy Device; Device
Lead sponsor: ProofPilot; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Adult Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
Interventions: 5-fluoro-2-deoxycytidine, tetrahydrouridine, laboratory biomarker analysis, reverse transcriptase-polymerase chain reaction, DNA methylation analysis; Drug · Other · Genetic
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection; Radiation · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Metastatic Prostate Cancer
Interventions: 11C-choline Injection; Drug
Lead sponsor: Global Isotopes, LLC d/b/a Zevacor Molecular; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Decatur, Illinois

Conditions: Recurrent Prostate Cancer
Interventions: High Intensity Focused Ultrasound; Device
Lead sponsor: SonaCare Medical; Industry
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 14
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Naples, Florida + 10 more

Conditions: High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
Interventions: Blood collection; Other
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania

Conditions: Prostate Adenocarcinoma, PSA Failure, PSA Progression, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Clinical Observation, Patient Observation, Questionnaire Administration, White Button Mushroom Extract; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Duarte, California • Glendora, California • Irvine, California + 4 more

Conditions: Prostate Cancer
Interventions: Pacritinib; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 85 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: Radiotherapy, Samarium 153; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 29
States / cities: Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more

Conditions: Prostate Adenocarcinoma
Interventions: 68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Procedure
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound

PROvenge Treatment and Early Cancer Treatment

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer

Exisulind Versus Placebo After Surgical Removal of the Prostate

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer

Phase II Laser Focal Therapy of Prostate Cancer

Luminance RED for Canker Sores

5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer